Wired Herald

Meningococcal Vaccines Market Will Be Hit $ 9.37 Billion By 2026

Press release   •   Jul 08, 2019 05:48 EDT

The Global Meningococcal Vaccines Market is expected to grow at noteworthy CAGR around 12.3 % throughout the forecast period and reach around US$ 9.34 billion by 2026.

Acumen Research and Consulting has recently published a research report on the Meningococcal Vaccines Market for the forecast period of 2019 to 2026, wherein, the global market has been analyzed and assessed in an extremely comprehensive manner. The research report on the Meningococcal Vaccines Market offers an extensive analysis of how the postoperative pain therapeutics landscape would evolve through 2026.

The research study on the Meningococcal Vaccines Market analyzes key drivers upholding product sales and prominent trends shaping the growth of the market. The research study not only focuses on the latent opportunities for the key stakeholders of the market, but also sheds light on the notable developments and future scope for innovation in the landscape.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1397

The report starts off with a quick executive summary, wherein, key takeaways have been highlighted for the readers to have a sneak peak at the key market segments. The research study by ARC on the market also talks about the macroeconomic and microeconomic factors having deep-rooted influences on global market growth. The research study on the Meningococcal Vaccines Market also offers a regional analysis, wherein, demand across every region has been comprehensively analyzed.

The report also analyzes the Meningococcal Vaccines Market on the basis of various segments, with drug type being a prominent one. A unique section in the report also offers a detailed breakdown on the basis of route of administration – which one is highly preferred and which one is minimally preferred.

Market Segmentation

Market Segmentation By Type:

  • Combination Vaccines
    • MenHibrix
    • Menitorix
  • Conjugate Vaccines
    • Menactra
    • MenAfriVac
    • Meningitec
    • Menjugate
    • Menveo
    • NeisVac-C
    • Nimenrix
    • NmVac4-DT
  • Polysaccharide
    • Mencevax
    • Menomune
    • NmVac4
    • Others
  • Men B Vaccines
    • Bexsero
    • Trumenba
  • Others

Market Segmentation By End User:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others

Market Segmentation by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Key Questions Answered in the Report

The report addresses key questions concerning the market evolution and overarching trends shaping global market growth. Some of the key questions answered in the report include-

What is the overall structure of the market?

What was the historical value and what is the forecasted value of the market?

What are the key product level trends in the market?

What are the market level trends in the market?

Which of the market players are leading and what are their key differential strategies to retain their stronghold?

Which are the most lucrative regions in the market space?

Buy this Premium Research Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1397

Research Methodology

The report on the Meningococcal Vaccines Market is based on an extensive and meticulous bottom up approach, which was used to determine the market size.

In the primary phase of the research methodology focus on, key stakeholders, including CEOs, presidents, vice presidents, chief medical officers, and product/sales/marketing managers were interviewed for the purpose of garnering unique insights into the dynamics of the market.

Market Participants:

Major companies contributing the global meningococcal vaccines market are Baxter International, Biomed Pvt. Ltd., GlaxoSmithKline plc, JN-International Medical Corporation, Novartis International, Nuron Biotech, Pfizer Inc., Sanofi SA, and Serum Institute of India Ltd.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Meningococcal Vaccines
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Meningococcal Vaccines Market By Type
1.2.2.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Meningococcal Vaccines Market Revenue Share By Type in 2017
1.2.2.3. Combination Vaccines
1.2.2.3.1. MenHibrix
1.2.2.3.2. Menitorix
1.2.2.4. Conjugate Vaccines
1.2.2.4.1. Menactra
1.2.2.4.2. MenAfriVac
1.2.2.4.3. Meningitec
1.2.2.4.4. Menjugate
1.2.2.4.5. Menveo
1.2.2.4.6. NeisVac-C
1.2.2.4.7. Nimenrix
1.2.2.4.8. NmVac4-DT
1.2.2.5. Polysaccharide
1.2.2.5.1. Mencevax
1.2.2.5.2. Menomune
1.2.2.5.3. NmVac4
1.2.2.5.4. Others
1.2.2.6. Men B Vaccines
1.2.2.6.1. Bexsero
1.2.2.6.2. Trumenba
1.2.2.6.3. Others
1.2.3. Meningococcal Vaccines Market By End User
1.2.3.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison By End User (2015-2026)
1.2.3.2. Global Meningococcal Vaccines Market Revenue Share By End User in 2017
1.2.3.3. Retail Pharmacies
1.2.3.4. Hospital Pharmacies
1.2.3.5. Others
1.2.4. Meningococcal Vaccines Market by Geography
1.2.4.1. Global Meningococcal Vaccines Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Meningococcal Vaccines Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Meningococcal Vaccines Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Meningococcal Vaccines Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Meningococcal Vaccines Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Meningococcal Vaccines Major Manufacturers in 2017

CHAPTER 4. MENINGOCOCCAL VACCINES MARKET BY FORM

4.1. Global Meningococcal Vaccines Revenue By Type
4.2. Combination Vaccines
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Conjugate Vaccines
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Polysaccharide
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Men B Vaccines
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. MENINGOCOCCAL VACCINES MARKET BY END USER

5.1. Global Meningococcal Vaccines Revenue By End User
5.2. Retail Pharmacies
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Hospital Pharmacies
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

6.1. North America Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Meningococcal Vaccines Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE MENINGOCOCCAL VACCINES MARKET BY COUNTRY

7.1. Europe Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET BY COUNTRY

8.1. Asia-Pacific Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

9.1. Latin America Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST MENINGOCOCCAL VACCINES MARKET BY COUNTRY

10.1. Middle East Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA MENINGOCOCCAL VACCINES MARKET BY COUNTRY

11.1. Africa Meningococcal Vaccines Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Meningococcal Vaccines Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End User, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Baxter International
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Biomed Pvt. Ltd.
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. GlaxoSmithKline plc
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. JN-International Medical Corporation
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Novartis International
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Nuron Biotech
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Pfizer Inc.
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Sanofi SA
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Serum Institute of India Ltd
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Others
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1397

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.